U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H25Cl2N7O
Molecular Weight 510.4191
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OTENABANT

SMILES

CCNC1(CCN(CC1)c2c3c(ncn2)n(-c4ccc(cc4)Cl)c(-c5ccccc5Cl)n3)C(=N)O

InChI

InChIKey=UNAZAADNBYXMIV-UHFFFAOYSA-N
InChI=1S/C25H25Cl2N7O/c1-2-31-25(24(28)35)11-13-33(14-12-25)22-20-23(30-15-29-22)34(17-9-7-16(26)8-10-17)21(32-20)18-5-3-4-6-19(18)27/h3-10,15,31H,2,11-14H2,1H3,(H2,28,35)

HIDE SMILES / InChI

Molecular Formula C25H25Cl2N7O
Molecular Weight 510.4191
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/?term=20211605 | https://www.ncbi.nlm.nih.gov/pubmed/?term=19102698

Otenabant (CP-945,598) is Pfizer developed as a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, which exhibits 10,000-fold greater selectivity against human CB2 receptor, for treatment of obesity. In clinical trial III Pfizer decided to discontinue the development program based on changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.699999999999999956 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Three double-blind, placebo-controlled, three-parallel-group, multicenter phase 3 trials were conducted to assess the efficacy and safety of CP-945,598 (OTENABANT) for weight loss and weight-loss maintenance. In total, 1,253 and 2,536 participants in the two 2-year multinational and North American studies were randomized to 10-mg CP-945,598 (n = 360; 718); 20-mg CP-945,598 (n = 534, 1,084) and placebo (n = 359, 734), respectively; and 975 participants were randomized to 10-mg CP-945,598 (n = 318); 20-mg CP-945,598 (n = 320); and placebo (n = 337) in the 1-year multinational diabetes trial.
Route of Administration: Oral
CP-945,598 (TENABANT) exhibits sub-nanomolar potency at human CB(1) receptors in both binding (K(i)=0.7 nM) and functional assays (K(i)=0.2 nM). The compound has low affinity (K(i)=7600 nM) for human CB(2) receptors.
Substance Class Chemical
Created
by admin
on Sat Jun 26 02:20:17 UTC 2021
Edited
by admin
on Sat Jun 26 02:20:17 UTC 2021
Record UNII
J8211Y53EF
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OTENABANT
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
OTENABANT [WHO-DD]
Common Name English
CP-945,598
Code English
OTENABANT [USAN]
Common Name English
4-PIPERIDINECARBOXAMIDE, 1-(8-(2-CHLOROPHENYL)-9-(4-CHLOROPHENYL)-9H-PURIN-6-YL)-4- (ETHYLAMINO)-
Systematic Name English
CP-945598
Code English
OTENABANT [INN]
Common Name English
1-(8-(2-CHLOROPHENYL)-9-(4-CHLOROPHENYL)-9H-PURIN-6-YL)-4-(ETHYLAMINO)PIPERIDINE-4- CARBOXAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29728
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL562668
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
FDA UNII
J8211Y53EF
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
EVMPD
SUB33607
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
PUBCHEM
10052040
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
CAS
686344-29-6
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
DRUG BANK
DB11745
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
NCI_THESAURUS
C84034
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
WIKIPEDIA
OTENABANT
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
INN
9009
Created by admin on Sat Jun 26 02:20:18 UTC 2021 , Edited by admin on Sat Jun 26 02:20:18 UTC 2021
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
FECAL; URINE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE -> PARENT
MAJOR
FECAL
METABOLITE -> PARENT
MAJOR
PLASMA
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
FECAL
METABOLITE -> PARENT
PLASMA
METABOLITE -> PARENT
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

IN HEALTHY HUMAN SUBJECTS

Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

IN HEALTHY HUMAN SUBJECTS

SINGLE DOSE